Sara Mangsbo

Publications

Selection of publications

• Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy (2010)
• Complement Activation by CpG in a Human Whole Blood Loop System (2009)
• CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity (2008)

Recent publications

• Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies (2023)
• Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer (2023)
• Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference? (2023)
• Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers (2023)
• Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines (2023)

All publications

Articles

• Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies (2023)
• Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer (2023)
• Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference? (2023)
• Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers (2023)
• Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines (2023)
• Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection (2022)
• Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1 (2022)
• Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination (2022)
• An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies (2022)
• SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection (2022)
• Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time (2022)
• Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 (2022)
• Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology (2022)
• Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines (2022)
• Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab (2022)
• Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer (2021)
• Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential (2021)
• Cancer Vaccines (2021)
• Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade (2021)
• Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients (2021)
• Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 (2021)
• Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers (2021)
• Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations (2021)
• An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses (2021)
• Fed-batch production assessment of a tetravalent bispecific antibody (2021)
• Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma (2021)
• Tumor localized agonistic anti-CD40 therapy and beyond (2020)
• Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy (2020)
• Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention (2020)
• Flodvåg av långtidssjuka covid-19-patienter väntar (2020)
• BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling (2019)
• Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics (2018)
• Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System (2018)
• Linking T cell epitopes to a common linear B cell epitope (2018)
• Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation (2017)
• Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment (2017)
• Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients (2017)
• Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients (2017)
• Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients (2017)
• Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer (2017)
• Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies (2016)
• Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients (2016)
• Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment (2016)
• The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses (2015)
• Kick-starting the cancer-immunity cycle by targeting CD40 (2015)
• The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity (2015)
• Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells (2015)
• Tim-3 and PD-1 (2014)
• The cerebrospinal fluid cytokine signature of multiple sclerosis (2014)
• The use of multiplex platforms for absolute and relative protein quantification of clinical material (2014)
• CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes (2014)
• A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells (2014)
• AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma (2014)
• Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo (2014)
• Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer (2014)
• Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer (2014)
• FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis (2014)
• T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis (2013)
• AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment (2013)
• FcγRIIb on Myeloid Cells and Intrinsic Renal Cells Rather than B Cells Protects from Nephrotoxic Nephritis (2013)
• Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone (2012)
• Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo (2012)
• Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells (2012)
• Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. (2011)
• Resolvin E1 Reduces Proinflammatory Markers in Human Pancreatic Islets in vitro (2010)
• AdCD40L Immunogene Therapy for Bladder Carcinoma (2010)
• Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy (2010)
• Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages (2009)
• Complement Activation by CpG in a Human Whole Blood Loop System (2009)
• CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity (2008)
• CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model (2008)
• Extending the immune phenotypes of lung cancer: Oasis in the desert
• Plasma proteomic analysis in non-small cell lung cancer patients treated with PD1/PD-L1 blockade
• An adaptable antibody-based platform for flexible synthetic peptide-based cargo delivery based on agonistic CD40-directed antibodies

Books

• Immunological Checkpoint Blockade and TLR Stimulation for Improved Cancer Therapy (2009)